Merck Cholesterol Pill Sales May Drop 20% More on Study Finding

Merck Cholesterol Pill Sales May Drop 20% More on Study Finding

Bloomberg - 42 minutes ago
By Shannon Pettypiece Nov. 10 (Bloomberg) -- Merck & Co. may face a third negative study result within two years for its cholesterol pills Vytorin and Zetia, which have lost 14 percent of sales ...